Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentKirsten Ras* oncogene: Significance of its discovery in human cancer researchImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsTargeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer TherapyAutomated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complexSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKTargeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug DiscoveryDeregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1(G93A) Amyotrophic Lateral Sclerosis mouse model.Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinomaDirect Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.Small-molecule modulation of Ras signaling.Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitorMutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.New Frontiers in DruggabilityInhibitors of Ras-SOS Interactions.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Therapeutic Approaches to RAS Mutation.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerKRAS - An Evolving Cancer TargetEffect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells.SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma.Current status of the development of Ras inhibitors.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Synthesis, DNA binding affinity and anticancer activity of novel 4H-benzo[g][1,2,3]triazolo[5,1-c][1,4]oxazocines.5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression.Sequence-specific DNA alkylation targeting for Kras codon 13 mutation by pyrrole-imidazole polyamide seco-CBI conjugates.Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression.Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).Selective Targeting of the KRAS Codon 12 Mutation Sequence by Pyrrole-Imidazole Polyamide seco-CBI Conjugates.Exploring the structural origins of cryptic sites on proteins.Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancerPersonalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma
P2860
Q26740619-FC74F415-1E82-4CFD-844A-2863166129C4Q26751212-B1AAEDD5-41BF-46FC-A778-195266E6A1E7Q26828959-02AD8207-6DEA-484E-BCBE-702BB2BAE67AQ27027458-3B0C1C88-B14F-4EF7-86B1-64AB860A1F05Q28078129-E350E5C4-2A8D-4F97-A05B-C41DE88ED4E1Q28539542-4F7E2996-51C1-424C-B17A-9EB22F892FC6Q28833740-844DD01C-A4AC-4F5C-B632-037B9124E0BDQ30390894-DC0ED836-11AE-463A-9A17-96C233C49D14Q33659976-9ECEC9DD-21BB-4D6F-97FC-ECF6009411ABQ34246014-D1A7B3D8-8D88-4931-9552-8A7480C0A70BQ34271187-FCD7ECAC-FE0D-44DD-ABC0-1BDF7A6BB7FFQ35188280-524F51C8-D79B-4261-B8CB-418643D87A33Q35207897-253B569E-03A2-4241-9521-68159ABD6DC2Q35213124-1ECD270D-5025-4133-B12C-F476B1C8B20FQ35730955-9265B404-7B4C-4422-B8A6-7EFC6E102854Q35859222-E52DCB70-C03B-4E51-ABB3-B95FF5F4FF9BQ36054290-0EAE021A-4F2A-413B-B45B-4F5C7407C2EBQ37122874-8C243ACD-FF6C-48D1-8371-76E05678300EQ37246286-977B02AD-887B-44E3-9C28-534728DDA6B5Q37261936-6B18E14B-434C-4364-9EAC-0B33E3913867Q37288375-4858C289-DF83-433C-AEB7-B1B2B01D1CF2Q37698902-9AAF93CD-479E-4480-9843-AB611C8C9BCEQ37709450-30933F17-20E7-4159-8667-AE098B3B3B79Q37743526-B5A86647-0AB4-4884-B949-173137CB5BE5Q38534932-3A7DC9C1-E803-4F73-8976-EE5EF89CFDA0Q38731776-745C2F9B-9407-4C45-8D43-F700D0792D7AQ38742130-67CE2337-FAD3-44BC-8A85-25105901BB91Q38858308-F06A4463-5BFB-40EC-B47F-A15F537181F1Q38891257-86537403-E1AC-4C62-A2F5-20B8376255E8Q39367990-10A05DB2-E5C5-4DAC-BEA7-B322AB69847AQ42048668-719472D2-CBA0-4EEC-91DC-7FEC2E6D9C4FQ44303195-A313BE9B-8218-4F37-BBFD-5704707DBAD3Q46357957-BC9192A9-7F64-4827-8AD4-2133EA06830AQ48031809-6F230DF3-AB96-471C-BFD8-E6A7886C8036Q48198158-36A665BC-978B-48D7-A3D2-860D4329E1F6Q48225794-2E22DD01-5445-4D24-B67F-94E9F73FBC0FQ53676358-7CBC0F82-8060-4237-878C-9840C1382632Q53834774-BDCFE063-93D5-45A6-BAE2-BF7F47F99886Q58552976-8A3822BE-811B-4237-9C44-59275CB11ECCQ58713519-9DBDCDC5-FBD9-4C1C-B6C1-01D9A6936B62
P2860
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@ast
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@en
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@nl
type
label
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@ast
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@en
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@nl
prefLabel
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@ast
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@en
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@nl
P2093
P2860
P356
P1476
Targeting mutant KRAS for anti ...... vel small molecule modulators.
@en
P2093
Brendan Frett
Christine E Kaiser
Hong-Yu Li
Yuanxiang Wang
P2860
P304
P356
10.1021/JM3017706
P407
P577
2013-04-23T00:00:00Z